DxTerity's REDI-Dx radiation test named 2013 NCT CBRNe Product of the Year
DxTerity was presented the award at the NCT CBRNe Asia conference in Kuala Lumpur, Malaysia. REDI-Dx was unanimously selected as the winner for its user benefit, economical consideration and offering a practical solution to CBRNe emergency responders in the world today.
"We are excited to receive this award," DxTerity CEO Bob Terbrueggen said. "It recognizes the importance of providing emergency responders with simple biodosimetry tools for testing individuals following a mass scale nuclear incident."
REDI-Dx is a blood-based, molecular, gene expression test used to estimate the amount of radiation exposure of an individual. It works by measuring the expression of a panel of genes sensitive to radiation exposure using blood samples taking through a fingerstick or venipuncture.
The test provides CBRNe emergency first responders with a useful tool that rapidly gives patient-specific information about levels of radiation poisoning. This enables first responders to recommend the right treatment for each patient based on radiation exposure.
REDI-Dx was developed in collaboration with Duke University Medical Center and was funded by the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority.